Singula Bio Analysis: $3M Raised
What is Singula Bio?
Singula Bio is a seed-stage biotechnology company spun out of the University of Oxford, focused on developing neoantigen-based cell therapies for patients with solid tumors. The company aims to provide individualized therapies to eliminate cancer and achieve long-term disease-free survival. Their approach combines immunological, medical, surgical, and computational technologies to target difficult-to-treat malignancies.
Location
John Radcliffe Hospital, Oxford, England OX3 9DS, United Kingdom
Employees
1-10
Founded
2020
Funding Status
Seed
Product Features & Capabilities
- Neoantigen-based cell therapies
- Immunological technologies
- Medical technologies
- Surgical technologies
- Computational technologies
Use Cases
Develop individualized cell therapies for ovarian cancer; Create therapies to prevent cancer recurrence; Utilize patient’s immune system to fight cancer; Address solid tumors with selective therapies; Innovate cancer treatment methods
Other Considerations
Founded by experts in cancer medicine and immunology; Team includes experienced professionals in live-cell therapy; Enzo Cerundolo's legacy drives the mission forward
See something that needs updating? Suggest edits to this profile.